trastuzumab biosimilar mAb-drug conjugate (Mabion)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nametrastuzumab biosimilar mAb-drug conjugate (Mabion)

Drug Alias NameMabion-HER2_ADC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMabion Sa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMabion Sa

Active IndicationsN/A

Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A